« Zurück
Startseite /
Veliparib (dihydrochloride)

Veliparib (dihydrochloride)

ArtNr	HY-10130-200mg
Hersteller	MedChem Express
CAS-Nr.	912445-05-7
Menge	200 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Typ	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37.\|[2]Penning TD, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009 Jan 22;52(2):514-23.\|[3]Albert JM, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007 May 15;13(10):3033-42.\|[4]Robert J. Kinders, et al. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res. Author manuscript; available in PMC 2009 Nov 1. Electrostatics Joint Conference. 2016 July.\|Harvard Medical School LINCS LIBRARY\|Int J Curr Res Acad Rev. 2017; 5(3): 53-64.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|Patent. US20200078369A1\|Patent. US20200129476A1\|Acta Pharmacol Sin. 2021 Jul 22.\|Biomed Res Int. 2023 Feb 6.\|BMC Cancer. 2022 Mar 23;22(1):312.\|Cancer Discov. 2017 Sep;7(9):984-998.\|Cancer Genet. 2019 Nov;239:26-32.\|Cancers (Basel). 2024 Nov 5;16(22):3728.\|Cancers (Basel). 2024 Oct 10;16(20):3441.\|Cell Death Dis. 2024 Dec 18;15(12):914.\|Cell Signal. 2025 Mar 2:111709.\|Cells. 2021, 10(3), 599.\|Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. \|Ecotoxicol Environ Saf. 2023 Mar 1;252:114630.\|Front Mol Biosci. 2021 Apr 29;8:633344.\|Front Oncol. 2021 Jul 9;11:681441.\|Int J Biol Macromol. 2023 May 12;124794.\|J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195.\|J Invest Dermatol. 2024 May 30:S0022-202X(24)00384-1.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Transl Med. 2024 Nov 26;22(1):1062.\|J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. \|Mol Cancer Ther. 2019 Nov;18(11):2063-2073.\|Nanomaterials. 2021, 11(6), 1514.\|Nat Commun. 2021 Jun 24;12(1):3931.\|Neoplasia. 2018 Mar 28;20(5):478-488. \|Neoplasia. 2025 Mar 16:63:101152.\|Neoplasia. 2019 Apr 24;21(6):533-544. \|Oncogene. 2022 Aug 6.\|Oncol Lett. 2025 January 7.\|Patent. US20180263995A1.\|Patent. US20180362972A1.\|Research Square Preprint. 2021 Feb.\|Research Square Preprint. 2024 Feb 21.\|Research Square Preprint. 2024 Nov 06.\|Theranostics. 2020 Jul 25;10(21):9477-9494.
Smiles	O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N.Cl.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ABT-888 dihydrochloride
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Autophagy; PARP
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	317.21
Product Description	Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 3.2 mg/mL\|H2O : 250 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Cell Cycle/DNA Damage; Epigenetics
Clinical information	Phase 3
Isoform	PARP1; PARP2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-10130-200mg-safety-datasheet.pdf